
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing piroxicam, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing piroxicam are listed in capsule form. No finished piroxicam product of any kind is listed in gel form.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Piroxicam is a long-acting nonsteroidal anti-inflammatory drug (NSAID) that compounding pharmacies prepare as topical gels and creams and as oral forms by prescription.
Piroxicam is an oxicam-class NSAID. It blocks the cyclooxygenase enzymes COX-1 and COX-2, which lowers production of prostaglandins, the signaling molecules behind pain, swelling and fever. It is unusual among NSAIDs for its long half-life, about 50 hours, so it is taken once daily and takes a week or more to reach steady levels. The manufactured product is an oral capsule sold as Feldene and as generics; it is FDA-approved for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. No topical piroxicam is manufactured in the United States, although a piroxicam gel is licensed in Ireland and other countries. A prescriber might order compounded piroxicam as a topical gel or cream for local application, in a strength or vehicle not manufactured, or combined with other topical pain ingredients. Compounded preparations are not FDA-approved and require a prescription.
Oral piroxicam carries two FDA boxed warnings. NSAIDs raise the risk of heart attack and stroke, which can be fatal and can happen early in treatment; piroxicam must not be used around coronary artery bypass surgery. NSAIDs also raise the risk of stomach and intestinal bleeding, ulcers and perforation, which can occur without warning, especially in older adults. Do not use piroxicam if aspirin or another NSAID has given you asthma, hives or an allergic reaction. Bleeding risk rises with blood thinners, aspirin, corticosteroids, and SSRI or SNRI antidepressants. Piroxicam can blunt blood pressure medicines and diuretics and raise lithium, methotrexate, digoxin and cyclosporine levels. Taking an NSAID at about 20 weeks of pregnancy or later may harm the unborn baby, so between 20 and 30 weeks use it only at the lowest dose for the shortest time your prescriber sets, and do not use it at about 30 weeks or later. LactMed reports low milk levels and no problems in older breastfed infants. Seek care for black stools, vomiting blood, chest pain, one-sided weakness, rash with fever or facial swelling. If side effects bother you, talk to your prescriber or pharmacist.
Piroxicam is a reversible, nonselective COX-1 and COX-2 inhibitor. Oral absorption is near complete with peak levels at 3 to 5 hours, protein binding about 99%, metabolism primarily by CYP2C9 with glucuronidation, and an elimination half-life averaging 50 hours; steady state takes 7 to 12 days. CYP2C9 *3/*3 carriers show roughly fivefold higher exposure, and the label suggests dose reduction in known poor metabolizers. Milk levels are 1 to 3 percent of maternal plasma. Labeled indications (Feldene capsules and generics): relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. Prescribers have ordered compounded topical piroxicam for localized musculoskeletal pain and soft tissue injury, the indication carried by the Irish-licensed Feldene Topigel, whose label reports steady-state plasma levels about one twentieth of those after oral dosing and, in animal studies, highest concentrations in the tissue beneath the application site; the AHFS monograph lists off-label oral use in acute gout, ankylosing spondylitis and dysmenorrhea. Dosing, strength and duration are per prescriber. Monitor blood pressure, renal function, CBC and GI bleeding signs with systemic exposure, plus INR with warfarin and lithium, methotrexate and digoxin levels when co-prescribed; the label carries a DRESS warning. Watch for local irritation and photosensitivity with topical use. Not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)